Entero Healthcare Solutions IPO: The debut missed analysts expectations of a 2 percent premium as the IPO had failed to attract investors with the issue getting subscribed only 1.53 times
Brokerage firms expect Sun Pharma to come out with a healthy set of numbers in Q3FY24, aided by specialty portfolio and domestic brand formulation, which will help offset US generic pressures.